Ani Pharmaceuticals (ANIP) EBT Margin (2011 - 2026)

Ani Pharmaceuticals has disclosed EBT Margin across 16 years of filings, most recently posting 16.94% for Q1 2026.

• EBT Margin for Q1 2026 came in at 16.94%, up 680.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 12.56% (up 1665.0% YoY), and the FY2025 annual result was 10.84%, up 1446.0% from the prior year.
• EBT Margin came in at 16.94% for Q1 2026 at Ani Pharmaceuticals, up from 12.74% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 18.43% in Q1 2024 to a low of 40.16% in Q1 2022.
• The 5-year median for EBT Margin is 2.03% (2023), against an average of 1.32%.
• Peak annual rise in EBT Margin reached 4457 bps in 2022, while the deepest fall reached 4084 bps in 2022.
• Ani Pharmaceuticals' EBT Margin stood at 6.08% in 2022, then jumped by 112 bps to 0.72% in 2023, then plunged by 1104 bps to 7.22% in 2024, then surged by 276 bps to 12.74% in 2025, then surged by 33 bps to 16.94% in 2026.
• The last three EBT Margin figures came in at 16.94% (Q1 2026), 12.74% (Q4 2025), and 14.84% (Q3 2025), per Business Quant data.